Relapsed Solid Tumors clinical trials

Reduced-intensity stem cell transplant for high-risk solid tumors

This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.

Combination therapy for tumors resistant to immunotherapy

This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.

EXS74539 Study for Advanced Solid Tumors

This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Testing LIT-00814 tablets for advanced solid tumors

This trial tests an experimental oral tablet (LIT-00814) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and to find the best dose.

Testing liquid blood samples in children with certain cancers

This trial studies “liquid biopsies,” which are blood tests, to help learn about specific cancers in children. It may help doctors monitor cancer and guide treatment using less invasive tests.

First-dose safety study of ABL503 for advanced cancers

This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.

Testing DB-1317 in advanced solid tumors

This trial tests an investigational drug (DB-1317) that targets a protein called ADAM9, found on some solid tumors. It is for people with advanced cancers that have not responded to other treatments, and aims to see if the drug is safe and works.

YK1101 for advanced solid tumors

This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.

HF50 for HER-2 positive and low-expression advanced tumors

This trial tests a new drug, HF50, in people with advanced solid tumors that are HER-2 positive or have low HER-2 levels. It may be an option if standard treatments have stopped working or are not tolerated.

NK cell therapy for advanced solid tumors

This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.

Testing SHR-9839 for advanced solid tumors

This Phase 1 trial studies SHR-9839, a new injection medicine, for people with advanced solid tumors that can’t be removed by surgery and have returned or stopped responding to standard care. It mainly aims to find a safe dose and see early signs of whether the treatment can work.

HLX316 immunotherapy for advanced solid tumors

This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.

NK521 infusion for advanced cancer with fluid buildup

This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.

TROP2-targeted NK cells for advanced solid tumors

This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.

Testing AP402 for her2-positive advanced solid tumors

This trial tests an experimental drug called AP402 for people with HER2-positive solid tumors that have spread or cannot be removed by surgery, and who have no standard treatment options left. The goal is to see if AP402 can shrink tumors or slow their growth.

Gene-guided chemo for kids with relapsed solid tumors

This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.

Study JCXH-212 to treat advanced solid tumors safely

This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.

Study drug for advanced solid cancers after standard treatments

This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.

Study of NWY001 for advanced solid tumors

This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.

Safety study of SBO-154 for advanced solid tumors

This trial tests a new drug called SBO-154 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have few or no other treatment choices.

SHR-1681 for advanced solid tumors that have stopped responding to treatment

This trial tests a new drug called SHR-1681 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if it can shrink tumors or slow their growth.

ABL103 for advanced solid tumors

This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.

Low-dose chemo under low blood sugar for advanced solid tumors

This trial tests whether giving low-dose chemotherapy while your blood sugar is low can help treat advanced solid tumors that have stopped responding to standard treatments. It aims to see if this approach is safe and effective.